Evogene (NASDAQ: EVGN) reported Q4 EPS of $0.06, $0.66 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $5.4 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.